FDA ensitrelvir coverage for business development, investment, and market access teams
Earlier
Critical impact NewsJun 5, 2026
FDA Approves Ensitrelvir (XOCOVA) as First Oral Option for COVID-19 Post-Exposure Prophylaxis
FDA · COVID-19 · 5 min
Sarah ChenHigh impact NewsJun 4, 2026
FDA Approves First Oral COVID-19 PEP Drug, Xocova
FDA · COVID-19 · 4 min
Michael RodriguezHigh impact AnalysisJun 2, 2026
FDA Approves Ensitrelvir for COVID-19 PEP
FDA · COVID-19 · 8 min
Sarah ChenPopular topics
- Drug Approvals 1,128 articles
- Clinical Trials 634 articles
- Regulatory Updates 687 articles
- FDA News 502 articles
- Press Releases 443 articles
- Oncology 443 articles
- Rare Diseases 141 articles
Explore intelligence
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways